Please ensure Javascript is enabled for purposes of website accessibility

British American Tobacco Claims It’s Close to a Plant-Based COVID-19 Vaccine

By Rhian Hunt – Apr 1, 2020 at 11:49AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company says production could start by June with the right support.

In one of the stranger plot twists to emerge from the coronavirus pandemic, British American Tobacco (BTI -1.33%) issued a news release today stating it is helping to develop a COVID-19 vaccine through a process using tobacco plants. Kentucky BioProcessing, a subsidiary of British American, is performing the actual research and development on the project.

This isn't Kentucky BioProcessing's first foray into medicine. The company produced Ebola treatment ZMapp in tobacco plants in 2014. While the effectiveness of ZMapp eventually proved lower than several other treatments, it still apparently increased survival rates. ZMapp was originally developed by Mapp Biopharmaceutical, but Kentucky BioProcessing was able to ramp up its production by rapidly producing the chimeric antibody treatment in tobacco plants.

A researcher at a British American Tobacco laboratory.

Image source: British American Tobacco.

Now, British American asserts, its subsidiary has developed an antigen that triggers an immune response in the human body, which responds with antibodies. The antigen comes from cloned COVID-19 genes and should theoretically vaccinate against the coronavirus. The company says it successfully grew the antigen inside tobacco plants and is now using a purified extract in pre-clinical tests.

Tobacco plants make good biochemical factories, according to British American, producing usable quantities of antigen in approximately six weeks rather than the months needed for standard methods. The antigens are also allegedly room temperature stable, so doses wouldn't require refrigeration to stay effective.

British American Tobacco hopes governments will assist with the process and posits that production of the vaccine could start in June of this year. It also claims that once fully operational, its tobacco-based production could crank out 1 million to 3 million vaccine doses weekly. The company says it will provide these doses on a not-for-profit basis, though it will otherwise continue to operate as a for-profit enterprise.

Rhian Hunt has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

British American Tobacco p.l.c. Stock Quote
British American Tobacco p.l.c.
$35.50 (-1.33%) $0.48

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.